Critical Contrast: Mazor Robotics (MZOR) & OraSure Technologies (OSUR)

Mazor Robotics (NASDAQ:MZOR) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares Mazor Robotics and OraSure Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mazor Robotics $64.95 million 23.64 -$12.41 million ($0.50) -116.64
OraSure Technologies $167.06 million 4.76 $30.94 million $0.51 25.51

OraSure Technologies has higher revenue and earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

21.7% of Mazor Robotics shares are owned by institutional investors. Comparatively, 92.0% of OraSure Technologies shares are owned by institutional investors. 2.9% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Mazor Robotics and OraSure Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mazor Robotics 1 3 0 0 1.75
OraSure Technologies 0 1 1 0 2.50

Mazor Robotics currently has a consensus target price of $51.67, suggesting a potential downside of 11.41%. OraSure Technologies has a consensus target price of $24.00, suggesting a potential upside of 84.47%. Given OraSure Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe OraSure Technologies is more favorable than Mazor Robotics.

Profitability

This table compares Mazor Robotics and OraSure Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mazor Robotics -37.29% -7.62% -6.66%
OraSure Technologies 9.49% 6.68% 5.97%

Volatility and Risk

Mazor Robotics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Summary

OraSure Technologies beats Mazor Robotics on 13 of the 14 factors compared between the two stocks.

About Mazor Robotics

Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic-guidance systems and complementary products are used to conduct spine and brain procedures in an accurate and secure manner. It also offers Mazor X, a renaissance system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel.

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply